Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Buy
53
CMRX Quote, Financials, Valuation and Earnings
Last price:
$3.34
Seasonality move
:
5.6%
Day range:
$2.91 - $3.17
52-week range:
$0.75 - $3.39
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.00x
Volume:
1.1M
Avg. volume:
7.9M
1-year change:
224.31%
Market cap:
$271.6M
Revenue:
$324K
EPS (TTM):
-$0.95
Analysts' Opinion
-
Consensus RatingChimerix has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Chimerix has an estimated upside of 178.15% from its current price of $3.02.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $3.02.
Fair Value
-
According to the consensus of 5 analysts, Chimerix has 178.15% upside to fair value with a price target of -- per share.
CMRX vs. S&P 500
-
Over the past 5 trading days, Chimerix has overperformed the S&P 500 by 2.01% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Chimerix does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Chimerix has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Chimerix reported revenues of $26K.
Earnings Growth
-
Chimerix has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Chimerix reported earnings per share of -$0.26.
Enterprise value:
135.4M
EV / Invested capital:
1.00x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.92x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-43.12%
Net Income Margin (TTM):
--
Return On Equity:
-48.22%
Return On Invested Capital:
-48.21%
Operating Margin:
-95357.69%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $33.1M | $1.1M | -- | $11K | $26K | |
| Gross Profit | $32.6M | -- | -- | -- | -- | |
| Operating Income | -$76.1M | -$96.1M | -$92.8M | -$26.7M | -$24.8M | |
| EBITDA | -$76M | -$96M | -$92.7M | -$26.7M | -$24.8M | |
| Diluted EPS | $1.75 | -$0.96 | -$0.95 | -$0.27 | -$0.26 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $90.2M | $128.5M | $291.1M | $200.6M | $140.9M | |
| Total Assets | $93.5M | $133.4M | $293.9M | $225.3M | $158.7M | |
| Current Liabilities | $7.4M | $26.3M | $17.7M | $15.5M | $22.2M | |
| Total Liabilities | $10.3M | $28.8M | $19.9M | $17M | $22.9M | |
| Total Equity | $83.2M | $104.6M | $274M | $208.3M | $135.8M | |
| Total Debt | -- | $14M | $250K | $125K | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$60.9M | -$74.5M | -$70.3M | -$17.9M | -$20.5M | |
| Cash From Investing | $321.6M | -$185.9M | $79.4M | $11.9M | $28.3M | |
| Cash From Financing | -$12.6M | $214K | $406K | $78K | $178K | |
| Free Cash Flow | -$61M | -$74.6M | -$70.4M | -$17.9M | -$20.5M | |
CMRX
Sector
Market Cap
$271.6M
$45.6M
Price % of 52-Week High
89.09%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
224.31%
-31.35%
Beta (5-Year)
1.018
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$2.90
200-day SMA
Buy
Level
$1.03
Bollinger Bands (100)
Buy
Level
0.5 - 1.7
Chaikin Money Flow
Sell
Level
-118.5M
20-day SMA
Buy
Level
$1.88
Relative Strength Index (RSI14)
Buy
Level
83.45
ADX Line
Buy
Level
19.93
Williams %R
Sell
Level
-14.3969
50-day SMA
Buy
Level
$1.31
MACD (12, 26)
Buy
Level
0.55
25-day Aroon Oscillator
Buy
Level
24
On Balance Volume
Neutral
Level
396.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.1127)
Buy
CA Score
(Annual)
Level (-0.2688)
Buy
Beneish M-Score
(Annual)
Level (-24.0611)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (4.4853)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
Stock Forecast FAQ
In the current month, CMRX has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CMRX average analyst price target in the past 3 months is --.
-
Where Will Chimerix Stock Be In 1 Year?
According to analysts, the consensus estimate is that Chimerix share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Chimerix?
Analysts are divided on their view about Chimerix share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Chimerix is a Sell and believe this share price will drop from its current level to --.
-
What Is Chimerix's Price Target?
The price target for Chimerix over the next 1-year time period is forecast to be -- according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CMRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Chimerix is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CMRX?
You can purchase shares of Chimerix via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Chimerix shares.
-
What Is The Chimerix Share Price Today?
Chimerix was last trading at $3.34 per share. This represents the most recent stock quote for Chimerix. Yesterday, Chimerix closed at $3.02 per share.
-
How To Buy Chimerix Stock Online?
In order to purchase Chimerix stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
73
PSIX alert for Dec 24
Power Solutions International [PSIX] is up 27.42% over the past day.
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 8.07% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 1.39% over the past day.
